PDCD1 and lung carcinoma: Among lung cancer patients, monotherapy with a PD-L1 inhibitor was associated with a significantly reduced risk of overall TRAEs compared with anti-PD-1 therapy (RR 1.18, 95 % CI 1.12–1.25, P < 0.0001).